MARLBOROUGH, Mass.,
Jan. 16, 2018 /PRNewswire/ --
Hologic, Inc. (Nasdaq: HOLX) announced today that it has priced and
allocated its previously announced private offering of $1 billion in aggregate principal amount of
senior notes as follows: (i) $600
million aggregate principal amount of additional 4.375%
senior notes due 2025 at an issue price of $1,000 per $1,000
and (ii) $400 million aggregate
principal amount of 4.625% senior notes due 2028 at an issue price
of $1,000 per $1,000.
The additional 2025 notes will be issued under the indenture
dated October 10, 2017 that governs
Hologic's 4.375% senior notes due 2025 dated October 10, 2017. The new 2028 notes will be
issued pursuant to a new indenture to be executed as of the closing
of the offering. The offering of the new 2028 notes and the
additional 2025 notes is expected to close on January 19, 2018, subject to customary closing
conditions.
Hologic intends to use the net proceeds of the offering and
available cash, which may include funds from its secured revolving
credit facility, to redeem its outstanding 5.25% senior notes due
2022 in the aggregate original principal amount of $1.0 billion.
The additional 2025 notes and the new 2028 notes will not be
registered under the Securities Act of 1933, as amended, or any
state securities laws. Unless so registered, the securities may not
be offered or sold in the United
States except pursuant to an exemption from, or in a
transaction not subject to, the registration requirements of the
Securities Act and applicable state securities laws. The additional
2025 notes and the new 2028 notes are being offered only to
qualified institutional buyers in reliance on Rule 144A under the
Securities Act, and outside the United
States in accordance with Regulation S under the Securities
Act.
This press release is neither an offer to sell nor a
solicitation of an offer to buy any of these securities, nor shall
there be any offer, solicitation or sale of these securities in any
jurisdiction where the offer, solicitation or sale is not
permitted. This press release shall not constitute a notice
of redemption with respect to the 5.25% senior notes due 2022.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women's health and well-being
through early detection and treatment. For more information on
Hologic, visit www.hologic.com.
Hologic, The Science of Sure, and associated logos are trademarks
and/or registered trademarks of Hologic, Inc. and/or its
subsidiaries in the United States
and/or other countries.
Forward-Looking Statements
This news release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions. Such
statements include, without limitation, the Company's intention to
issue the additional 2025 notes and the new 2028 notes and the use
of proceeds of the offering, including the Company's plans to
redeem its outstanding 5.25% senior notes due 2022. These
forward-looking statements are subject to known and unknown risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. The
offering may also be adversely affected by prevailing credit
markets, which have been subject to significant volatility, or
adverse changes to Hologic's business or prospects. Hologic cannot
assure it will complete the issuance of the additional 2025 notes
and the new 2028 notes on favorable terms, if at all. In addition,
Hologic's decision to redeem its outstanding 5.25% senior notes due
2022 shall be contingent on the completion of this offering and the
receipt of its proceeds. The risks included above are not
exhaustive. Other factors that could adversely affect the Company's
business and prospects are described in the filings made by Hologic
with the SEC. Hologic expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
such statements presented herein to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such statements are based.
Contact
Michael Watts
Vice President, Investor Relations and
Corporate Communications
(858) 410-8588
View original
content:http://www.prnewswire.com/news-releases/hologic-announces-pricing-of-offering-of-1-billion-of-senior-notes-300583643.html
SOURCE Hologic, Inc.